Jiesi Luo

Graduate Research Assistant
(May 2008 - present)

Email: luojiesi@msu.edu

Jiesi earned his bachelor's degree in Animal Science from China Agricultural University, Beijing, China in 2007. He is now pursuing his PhD under the guidance of Dr Cibelli and his project includes investigation of pluripotency of animal embryonic stem cells, and mammalian and early embryonic development. His proposed project focuses on generation of induced pluripotent stem cells (iPSCs) from canine somatic cells. The aim of his project is to elucidate the potential requirements for producing iPSCs from dog adult stem cells, in an effort to help form a template for development of regenerative medicine to aid dogs paralyzed by spinal cord injuries. The second area of Jiesi's studies include investigation of the anti-apoptotic effect of sphingosine-1-phosphate on in vitro development of bovine embryos.

Eun-Ah Chang (PI)

(July 2004 - present)

Email: changeu@msu.edu

Eun-Ah Chang is a Research Assistant Professor in the Cellular Reprogramming Laboratory (CRL). She graduated from the Medical College of Chung-Ang University at Seoul in Korea, 1992. Dr. Chang completed her residency in Clinical Pathology at Chung-Ang Medical Hospital, and she did her fellowship training in Hemato-Oncology with Bong-Hak Hyun, MD, PhD at Ajou University Hospital in 1999. She received her PhD in 2000 and her PhD thesis was involved in the Clinical significance of p53, MDM2, CyclinD1 protein expression in patients with Multiple Myeloma'. She has a board certified in clinical pathology of Korea. Dr. Chang has worked as a Clinical Assistant Professor in the Department of Laboratory Medicine at the University of Korea before she joined the CRL. At the University of Korea, her main research there involved Diagnostic Hemato-oncology, and Immunology.

Her early research at the CRL showed a relationship between neuronal differentiation potential of hESCs and psychoneurologic drug (Prozac) treatment for the first time. More recently, she has been responsible for the generation of human pluripotent stem cells from somatic cells using reprogramming vectors. Her activities include generating and characterizing induced pluripotent stem (iPS) cells from pre-clinical species and humans as well as optimizing in vitro differentiation protocols that deliver terminally differentiated cell types with defined functional characters.